Molecular Profiling to Guide Cardiac and Thoracic Surgery (C) (No CME)
This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Cancer.
The science of molecular profiling is moving along at a pace at which surgeons may have a difficult time maintaining a relevant and working knowledge. Understanding the fundamental aspects of this topic can help surgeons stay abreast of ongoing discoveries and also remain well versed in their interactions with their nonsurgical peers. Furthermore, a strong working knowledge of this topic can allow surgeons to recognize when genomic profiling may be of greatest benefit to their patients. Having an understanding of topics such as fundamental differences between genomics and proteomics, whole exome sequencing, the cancer genome atlas, and the role of genomic profiling guiding therapy in lung cancer and esophageal cancer, as well as favorably altering outcomes associated with cardiac surgery, can be a potentially useful body of knowledge.
Y. Joseph Woo, MD, FACS, Stanford, CA
- Molecular Profiling in Esophageal Cancer
Dennis A. Wigle, MD, PhD, FACS, Rochester, MN
- Molecular Correlates for Classification of Lung Cancer
Matthew J. Bott, MD, New York, NY
- Exosomes in Heart Failure: Biomarker and Therapy
Pavan Atluri, MD, FACS, Philadelphia, PA
- Serum-Based Molecular Markers of Post-Cardiopulmonary Bypass Neurologic Injury
Neel R. Sodha, MD, Providence, RI
- Transcriptome Profiling in Postoperative Atrial Fibrillation
Anson M. Lee, MD, Palo Alto, CA
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
- For questions about the course content, please contact email@example.com.
- If you have any technical questions, contact firstname.lastname@example.org.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website: http://www.accme.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions/financial-relationships-and-conflicts-interest
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures.)
Faculty and Disclosures
Y. Joseph Woo, MD, FACS, Stanford, CA - No Disclosures
Dennis A. Wigle, MD, PhD, FACS, Rochester, MN - No Disclosures
Matthew J. Bott, MD, New York, NY - AstraZeneca Pharmaceuticals: Consulting Fee: Consultant
Pavan Atluri, MD, FACS, Philadelphia, PA - No Disclosures
Neel R. Sodha, MD, Providence, RI - No Disclosures
Anson M. Lee, MD, Palo Alto, CA - No Disclosures
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - No Disclosures
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - No Disclosures
David C. Borgstrom, MD, FACS, Morgantown, WV - No Disclosures
Daniel L. Dent, MD, FACS, San Antonio, TX - No Disclosures
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Audra A. Duncan, MD, FACS, London, ON - No Disclosures
Mariam F. Eskander, MD, Boston, MA - No Disclosures
Paula Ferrada, MD, FACS, Richmond, VA - No Disclosures
Neil H. Hyman, MD, FACS, Chicago, IL - No Disclosures
Martin S. Karpeh, Jr., MD, FACS, New York, NY - No Disclosures
Dennis H. Kraus, MD, FACS, New York, NY - No Disclosures
Kenneth W. Sharp, MD, FACS, Nashville, TN - No Disclosures
David A. Spain, MD, FACS, Stanford, CA - No Disclosures
Mary T. Hawn, MD, FACS, Stanford, CA - No Disclosures
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - No Disclosures
Barbara Lee Bass, MD, FACS, FRCS(Hon), Houston, TX - No Disclosures
Quan-Yang Duh, MD, FACS, San Francisco, CA - No Disclosures
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - No Disclosures
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - No Disclosures
Valerie W. Rusch, MD, FACS, New York, NY - No Disclosures
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee and speakers were required to disclose all financial relationships. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the session. The planning committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please advise us of the circumstances on the session evaluation form.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.
The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
A Certificate of Completion will be awarded.
This educational activity is not eligible for CME or CE credits.
- 0.00 AMA PRA Category 1 Credit™
- 0.00 Certificate of Completion
- 0.00 Self Assessment Credit